• Je něco špatně v tomto záznamu ?

Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index

A. Sýkorová, V. Procházka, H. Móciková, A. Janíková, R. Pytlík, D. Belada, K. Benešová, P. Klener, J. Ďuraš, L. Smolej, V. Campr, P. Blahovcová, M. Trněný

. 2022 ; 69 (6) : 1466-1473. [pub] -

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004918

Burkitt lymphoma (BL) is a rare subtype of non-Hodgkin's lymphoma with an aggressive course. To refine the individual patient's prognosis, the International Prognostic Index for BL (BL-IPI) was recently developed and 4 risk factors (RF) were determined as optimal prognostic cut-off by multivariate analysis: age ≥40 years, lactate dehydrogenase >3× upper limit of normal, ECOG performance status ≥2, and central nervous system involvement. The BL-IPI distinguishes 3 prognostic groups, low (without RF), intermediate (1 RF), and high risk (2-4 RF), with significant differences in survival. The aim of the current project was to perform an external validation of the BL-IPI in 101 patients from the Registry of Czech Lymphoma Study Group diagnosed between 1999 and 2016 (median age, 45 years). The median follow-up was 50.4 months. The induction treatment included rituximab plus chemotherapy in 82% and chemotherapy alone in 18%. The overall response rate was 78% and the complete remission rate was 73%. According to BL-IPI, low/intermediate/high risk was present in 21/35/45% of patients, showing high similarity to the training BL-IPI US (United States) dataset (18/36/46%). There were significant differences in progression-free survival (PFS) and overall survival (OS) between patients with high vs. intermediate risk (PFS: hazard ratio 0.16, 95% confidence interval 0.08-0.31, p<0.0001; OS: hazard ratio 0.17, 95% confidence interval 0.09-0.35, p<0.0001) but not between patients with low vs. intermediate risk. The 3-year OS probability according to BL-IPI with low/intermediate/high risk was 96/76/59% in the BL-IPI training dataset vs. 95/85/45% in our external validation cohort; the 3-year PFS probability with low/intermediate/high risk was 92/72/53% in the BL-IPI training dataset vs. 95/85/42% in our cohort. In summary, our external validation of the BL-IPI confirmed a good separation of high-risk patients, who have a poor prognosis and for whom the new therapeutic approaches are needed; patients with low and intermediate risk had favorable clinical outcomes, and differences between these groups were not significant, likely due to a small number of patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004918
003      
CZ-PrNML
005      
20230425171808.0
007      
ta
008      
230418s2022 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2022_221030N1064 $2 doi
035    __
$a (PubMed)36591807
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Sýkorová, Alice $u 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
245    10
$a Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index / $c A. Sýkorová, V. Procházka, H. Móciková, A. Janíková, R. Pytlík, D. Belada, K. Benešová, P. Klener, J. Ďuraš, L. Smolej, V. Campr, P. Blahovcová, M. Trněný
520    9_
$a Burkitt lymphoma (BL) is a rare subtype of non-Hodgkin's lymphoma with an aggressive course. To refine the individual patient's prognosis, the International Prognostic Index for BL (BL-IPI) was recently developed and 4 risk factors (RF) were determined as optimal prognostic cut-off by multivariate analysis: age ≥40 years, lactate dehydrogenase >3× upper limit of normal, ECOG performance status ≥2, and central nervous system involvement. The BL-IPI distinguishes 3 prognostic groups, low (without RF), intermediate (1 RF), and high risk (2-4 RF), with significant differences in survival. The aim of the current project was to perform an external validation of the BL-IPI in 101 patients from the Registry of Czech Lymphoma Study Group diagnosed between 1999 and 2016 (median age, 45 years). The median follow-up was 50.4 months. The induction treatment included rituximab plus chemotherapy in 82% and chemotherapy alone in 18%. The overall response rate was 78% and the complete remission rate was 73%. According to BL-IPI, low/intermediate/high risk was present in 21/35/45% of patients, showing high similarity to the training BL-IPI US (United States) dataset (18/36/46%). There were significant differences in progression-free survival (PFS) and overall survival (OS) between patients with high vs. intermediate risk (PFS: hazard ratio 0.16, 95% confidence interval 0.08-0.31, p<0.0001; OS: hazard ratio 0.17, 95% confidence interval 0.09-0.35, p<0.0001) but not between patients with low vs. intermediate risk. The 3-year OS probability according to BL-IPI with low/intermediate/high risk was 96/76/59% in the BL-IPI training dataset vs. 95/85/45% in our external validation cohort; the 3-year PFS probability with low/intermediate/high risk was 92/72/53% in the BL-IPI training dataset vs. 95/85/42% in our cohort. In summary, our external validation of the BL-IPI confirmed a good separation of high-risk patients, who have a poor prognosis and for whom the new therapeutic approaches are needed; patients with low and intermediate risk had favorable clinical outcomes, and differences between these groups were not significant, likely due to a small number of patients.
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    12
$a Burkittův lymfom $x farmakoterapie $7 D002051
650    _2
$a prognóza $7 D011379
650    12
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $7 D016403
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a registrace $7 D012042
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Procházka, Vít $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Móciková, Heidi $u Department of Clinical Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Janíková, Andrea $u Department of Hematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Pytlík, Robert $u 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic $u Department of Cell Therapy, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
700    1_
$a Benešová, Kateřina $u 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic
700    1_
$a Klener, Pavel $u 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic
700    1_
$a Ďuraš, Juraj $u Department of Hemato-Oncology, Faculty of Medicine, Ostrava, Czech Republic
700    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
700    1_
$a Campr, Vít $u Institute of Pathology, University Hospital Motol, Prague, Czech Republic
700    1_
$a Blahovcová, Petra $u Data Management Office, 1st Department of Internal Medicine-Department of Hematology, First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic
700    1_
$a Trněný, Marek $u 1st Department of Medicine-Department of Hematology, Charles University, General Hospital, Prague, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 69, č. 6 (2022), s. 1466-1473
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36591807 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171804 $b ABA008
999    __
$a ok $b bmc $g 1925170 $s 1191127
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 69 $c 6 $d 1466-1473 $e - $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace